In addition, the phase II-III trial (NCT05426486) is comparing ARX788 combined with pyrotinib maleate versus TCHP (trastuzumab, pertuzumab, docetaxel and carboplatin) as neoadjuvant treatment in patients with stage II-III HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.